Should I do chemotherapy before or after surgery for HER2-Positive Breast Cancer

Chemotherapy Timing for HER2-Positive Breast Cancer

This is an important question that depends on several factors specific to your situation. Let me explain how doctors think about this decision and what you should discuss with your team.

How Doctors Approach This Decision

The timing of chemotherapy relative to surgery—called neoadjuvant therapy (before surgery) versus adjuvant therapy (after surgery)—is determined by your individual clinical picture, including:

• Stage of your cancer (size, lymph node involvement, whether it has spread)
• HER2 expression level (how much HER2 protein your cancer is producing)
• Overall health and ability to tolerate treatment
• Your specific tumor characteristics (hormone receptor status, grade)

General Treatment Approaches for HER2-Positive Breast Cancer

Neoadjuvant approach (chemotherapy BEFORE surgery):

• Chemotherapy + HER2-targeted therapy (like trastuzumab/Herceptin) given first
• Goal: Shrink the tumor before surgery, making it easier to remove
• Advantage: Doctors can see how your tumor responds to treatment
• Often used for larger or more advanced tumors

Adjuvant approach (chemotherapy AFTER surgery):

• Surgery performed first to remove the tumor
• Chemotherapy + HER2-targeted therapy given afterward
• Often used for smaller, earlier-stage cancers
• Advantage: Tumor is already removed

Important context: According to the webinar on HER2-positive breast cancer treatment, newer drugs like Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate that delivers chemotherapy directly to HER2-positive cancer cells, represent advances in how we treat this cancer type. Your oncologist may discuss whether this newer option is appropriate for your case.

Critical Questions to Ask Your Oncologist

1. What is the stage of my cancer, and does that influence whether I should have chemotherapy before or after surgery?

2. What is my HER2 expression level, and how does that affect the treatment sequence?

3. Are there newer HER2-targeted therapies like Enhertu that might be appropriate for my situation?

4. What is the expected outcome with each approach (before vs. after surgery)?

5. Are there any clinical trials available that might offer additional options?

6. How will we monitor my response to treatment, and what happens if the cancer doesn't respond as expected?

Why This Matters

The sequence of treatment can affect:

• How much the tumor shrinks before surgery
• Whether you need less extensive surgery
• Your overall survival and recurrence risk
• Side effects you may experience

Your oncologist will weigh all these factors based on your complete medical picture—something only they can do with access to your pathology report, imaging, and health history.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.